Onxeo S.A.
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops developing VIO-01, which is in Phase 1/2 of the VIO-01 clinical study, a Pan-DDR DNA decoy targeting multiple proteins and repair pathways in preclinical development; an… Read more
Onxeo S.A. (0NWK) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, Onxeo S.A. (0NWK) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Onxeo S.A. - Net Assets Trend (None–None)
This chart illustrates how Onxeo S.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Onxeo S.A. (None–None)
The table below shows the annual net assets of Onxeo S.A. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Onxeo S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Onxeo S.A. Competitors by Market Cap
The table below lists competitors of Onxeo S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tonner Drones S.A.
PA:ALTD
|
$7.86 Million |
|
ECOUP OYJ EO 1
F:62H
|
$7.86 Million |
|
Dyandra Media International PT
JK:DYAN
|
$7.86 Million |
|
Asuransi Harta Aman Pratama Tbk PT
JK:AHAP
|
$7.86 Million |
|
Tong Hua Holding Public Company Limited
BK:TH
|
$7.86 Million |
|
Freightos Limited Warrants
NASDAQ:CRGOW
|
$7.86 Million |
|
Bolt Biotherapeutics
NASDAQ:BOLT
|
$7.86 Million |
|
PARKER-HANNIFIN CO. - Dusseldorf Stock Exchang
DU:PAR
|
$7.85 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Onxeo S.A.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Onxeo S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Onxeo S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Onxeo S.A.'s net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Onxeo S.A. (0NWK) | €- | N/A | N/A | $7.86 Million |
| Nyfosa AB (0A0K) | $2.92 Billion | 39.50% | 2.88x | $973.31 Million |
| High Templar Tech Limited (0A2T) | $12.52 Billion | 4.70% | 0.13x | $255.82 Million |
| Strategy Inc (0A7O) | $51.04 Billion | -7.54% | 0.21x | $40.17 Billion |
| NACON SASU (0A9N) | $67.54 Million | 15.85% | 1.20x | $7.64 Million |
| Antin Infrastructure Partners (0AA5) | $23.79 Million | 108.98% | 1.09x | $573.10 Million |
| Truecaller AB Series B (0AA7) | $1.41 Billion | 18.30% | 0.20x | $281.60 Million |
| Brockhaus Technologies AG (0AAW) | $254.92 Million | -6.23% | 1.68x | $74.40 Million |
| Hyloris Pharmaceuticals S.A. (0AB6) | $48.06 Million | -24.09% | 0.32x | $71.96 Million |
| Kalray S.A. (0ABT) | $28.43 Million | -41.56% | 0.67x | $33.84 Million |
| Webuild S.p.A. (0BJP) | $1.43 Billion | 10.29% | 7.14x | $1.13 Billion |